{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:10:33Z","timestamp":1783476633330,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570202"],"award-info":[{"award-number":["82570202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04397-w","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:21:33Z","timestamp":1777908093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion"],"prefix":"10.1007","volume":"75","author":[{"given":"Yuanmei","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Difan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezhou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"4397_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A et al (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"issue":"1","key":"4397_CR2","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, Dinardo CD, Kadia TM et al (2025) Acute myeloid leukemia management and research in 2025 [J]. CA Cancer J Clin 75(1):46\u201367","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4397_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, Dinardo C et al (2021) Acute myeloid leukemia: current progress and future directions [J]. Blood Cancer J 11(2):41","journal-title":"Blood Cancer J"},{"issue":"1","key":"4397_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C (2023) Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol 16(1):29","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4397_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/PPO.0000000000000574","volume":"28","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Wei AH (2022) Evolution of therapy for older patients with acute myeloid leukemia: how should we use currently available agents? Cancer J 28(1):67\u201372","journal-title":"Cancer J"},{"issue":"4","key":"4397_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99(4):615\u2013624","journal-title":"Am J Hematol"},{"issue":"13","key":"4397_CR7","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM et al (2022) Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia [J]. Blood Adv 6(13):3997\u20134005","journal-title":"Blood Adv"},{"issue":"6","key":"4397_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, Dinardo C et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents [J]. Leukemia 28(6):1280\u20131288","journal-title":"Leukemia"},{"issue":"10","key":"4397_CR9","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1111\/cas.70139","volume":"116","author":"X Peng","year":"2025","unstructured":"Peng X, Li Y, Tang F et al (2025) BCL-2 inhibitor regulates number, function, and antitumor immunity of T cells by influencing glycolysis in AML [J]. Cancer Sci 116(10):2657\u20132676","journal-title":"Cancer Sci"},{"key":"4397_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1386517","volume":"15","author":"G Corradi","year":"2024","unstructured":"Corradi G, Forte D, Cristiano G et al (2024) Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1(+)TIM3(+) exhausted CD8(+) T cells. Front Immunol 15:1386517","journal-title":"Front Immunol"},{"issue":"4","key":"4397_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V et al (2019) Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation [J]. Nat Med 25(4):603\u2013611","journal-title":"Nat Med"},{"key":"4397_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, Minden MD, Hood T et al (2020) Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0463","journal-title":"Sci Transl Med"},{"issue":"3","key":"4397_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","volume":"8","author":"B Jia","year":"2018","unstructured":"Jia B, Wang L, Claxton DF et al (2018) Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J 8(3):34","journal-title":"Blood Cancer J"},{"key":"4397_CR14","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","volume":"10","author":"A Xia","year":"2019","unstructured":"Xia A, Zhang Y, Xu J et al (2019) T cell dysfunction in cancer immunity and immunotherapy [J]. Front Immunol 10:1719","journal-title":"Front Immunol"},{"issue":"3","key":"4397_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S et al (2019) Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study. Cancer Discov 9(3):370\u2013383","journal-title":"Cancer Discov"},{"issue":"2","key":"4397_CR16","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1002\/ajh.26043","volume":"96","author":"H Zheng","year":"2021","unstructured":"Zheng H, Mineishi S, Claxton D et al (2021) A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia [J]. Am J Hematol 96(2):E46-e50","journal-title":"Am J Hematol"},{"key":"4397_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020236","author":"K Giannopoulos","year":"2019","unstructured":"Giannopoulos K (2019) Targeting immune signaling checkpoints in acute myeloid leukemia. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8020236","journal-title":"J Clin Med"},{"issue":"4","key":"4397_CR18","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I (2020) Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest 130(4):1552\u20131564","journal-title":"J Clin Invest"},{"issue":"Supplement_1","key":"4397_CR19","doi-asserted-by":"publisher","first-page":"830-","DOI":"10.1182\/blood-2019-131494","volume":"134","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, Sharma P, Allison JP et al (2019) Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in relapsed\/refractory acute myeloid leukemia: A non-randomized, prospective, phase 2 study. Blood 134(Supplement_1):830-","journal-title":"Blood"},{"issue":"10","key":"4397_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM et al (2023) CD8(+) T cells in the cancer-immunity cycle. Immunity 56(10):2231\u20132253","journal-title":"Immunity"},{"issue":"5","key":"4397_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","volume":"18","author":"SA Lim","year":"2022","unstructured":"Lim SA, Su W, Chapman NM et al (2022) Lipid metabolism in T cell signaling and function [J]. Nat Chem Biol 18(5):470\u2013481","journal-title":"Nat Chem Biol"},{"key":"4397_CR22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191920","author":"T Manzo","year":"2020","unstructured":"Manzo T, Prentice BM, Anderson KG et al (2020) Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20191920","journal-title":"J Exp Med"},{"issue":"7","key":"4397_CR23","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu S, Chaudhary O, RODR\u00edGUEZ-MORALES P et al (2021) Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity 54(7):1561\u201377.e7","journal-title":"Immunity"},{"issue":"5","key":"4397_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, Xiao L, Liu L et al (2021) CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability [J]. Cell Metab 33(5):1001\u201312.e5","journal-title":"Cell Metab"},{"issue":"1","key":"4397_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma X, Bi E, Lu Y et al (2019) Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab 30(1):143\u201356.e5","journal-title":"Cell Metab"},{"issue":"6","key":"4397_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101592","volume":"5","author":"HZ Guo","year":"2024","unstructured":"Guo HZ, Feng RX, Zhang YJ et al (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML [J]. Cell Rep Med 5(6):101592","journal-title":"Cell Rep Med"},{"issue":"20","key":"4397_CR27","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J]. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"12","key":"4397_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6HNER","year":"2022","unstructured":"D\u00f6HNER H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"26","key":"4397_CR29","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"3","key":"4397_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R et al (2019) Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20(3):326\u2013336","journal-title":"Nat Immunol"},{"issue":"2","key":"4397_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies A, Zehn D, Utzschneider DT (2020) Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol 20(2):128\u2013136","journal-title":"Nat Rev Immunol"},{"key":"4397_CR32","first-page":"334","volume":"22","author":"M Jim\u00e9nez-Fern\u00e1ndez","year":"2023","unstructured":"Jim\u00e9nez-Fern\u00e1ndez M, de la Fuente H, Mart\u00edn P et al (2023) Unraveling CD69 signaling pathways, ligands and laterally associated molecules [J]. Excli J 22:334\u201351","journal-title":"Excli J"},{"issue":"2","key":"4397_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","volume":"254","author":"E Aktas","year":"2009","unstructured":"Aktas E, Kucuksezer UC, Bilgic S et al (2009) Relationship between CD107a expression and cytotoxic activity [J]. Cell Immunol 254(2):149\u2013154","journal-title":"Cell Immunol"},{"key":"4397_CR34","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell M, Peleteiro Ra\u00edndo A, Climent Medina J et al (2022) Immune checkpoint inhibitors in acute myeloid leukemia: A meta-analysis [J]. Front Oncol 12:882531","journal-title":"Front Oncol"},{"issue":"6","key":"4397_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jcph.858","volume":"57","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Shebley M, Salem AH (2017) Quantitative prediction of the effect of CYP3A inhibitors and inducers on Venetoclax pharmacokinetics using a physiologically based pharmacokinetic model. J Clin Pharmacol 57(6):796\u2013804","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"4397_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I (2020) An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 16(9):809\u2013822","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"4397_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD Dinardo","year":"2020","unstructured":"Dinardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"12","key":"4397_CR38","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N (2025) How I treat patients with AML using azacitidine and venetoclax. Blood 145(12):1237\u20131250","journal-title":"Blood"},{"issue":"8","key":"4397_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2022) Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine [J]. J Clin Oncol 40(8):855\u2013865","journal-title":"J Clin Oncol"},{"issue":"1","key":"4397_CR40","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1186\/s12885-025-14167-z","volume":"25","author":"JF Bai","year":"2025","unstructured":"Bai JF, Wang T, Li JT et al (2025) Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study. BMC Cancer 25(1):990","journal-title":"BMC Cancer"},{"key":"4397_CR41","doi-asserted-by":"publisher","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","volume":"8","author":"E Climent","year":"2021","unstructured":"Climent E, Benaiges D, Pedro-Botet J (2021) Hydrophilic or Lipophilic Statins? [J]. Front Cardiovasc Med 8:687585","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"4397_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.43861","volume":"6","author":"MO Murto","year":"2023","unstructured":"Murto MO, Simolin N, Arponen O et al (2023) Statin use, cholesterol level, and mortality among females with breast cancer. JAMA Netw Open 6(11):e2343861","journal-title":"JAMA Netw Open"},{"issue":"33","key":"4397_CR43","doi-asserted-by":"publisher","first-page":"14733","DOI":"10.1073\/pnas.1009731107","volume":"107","author":"HT Jin","year":"2010","unstructured":"Jin HT, Anderson AC, Tan WG et al (2010) Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection [J]. Proc Natl Acad Sci U S A 107(33):14733\u201314738","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04397-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:21:34Z","timestamp":1777908094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04397-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4397"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04397-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Approval was obtained from the following institutional review boards: the Independent Ethics Committee of Shanghai Ninth People\u2019s Hospital (SH9H-2023-T9-1); and the Ethics Committee of Shidong Hospital, Shanghai Yangpu District (2023-062-01).Written informed consent was obtained from all participants prior to enrollment. This study was registered at the Chinese Clinical Trials Registry (registration number: ChiCTR 2500111931).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"162"}}